We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Casma Therapeutics is taking aim at a range of conditions through a "long-neglected" cell process: its garbage disposal. Armed with $58.5 million in series A cash from Third Rock, the biotech is working on a platform ...